Rapamycin, an anti-rejection drug for organ transplant patients, has now been shown to increases survival in and delayed symptoms of Leigh’s syndrome. The drug appears to cause a metabolic switch that bypasses the mitochondrial deficiency.
Currently browsing: Matt Kaeberlein
Search UW Today
- Gene therapy leads to robust improvements in animal model of fatal muscle disease January 22, 2014
- Health Sciences Digest: Alcoholism in homeless, medical phone apps, aging with chronic disability May 20, 2014
- Two common drugs may help treat deadly Middle East Respiratory Syndrome September 10, 2013